Stocktoria
20/20 Biolabs, Inc. AIDX
20/20 Biolabs, Inc. (AIDX) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $2.0M at a -182.8% net margin.
Beneish M-score: -4.25 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AIDX | 20/20 Biolabs, Inc. | 4/9 | — | — | — |
| BNBX | BNB PLUS CORP. | 2/9 | — | — | — |
| NEO | NEOGENOMICS INC | 5/9 | 1.46 | — | +10.1% |
| ULS | UL Solutions Inc. | 6/9 | 3.1 | 60.8 | +6.4% |
| GOOG | Alphabet Inc. | 5/9 | 6.79 | 31.1 | +15.1% |
| MSFT | MICROSOFT CORP | 6/9 | 4.49 | 20.7 | +17.8% |
| META | Meta Platforms, Inc. | 4/9 | 5.34 | 23.1 | +22.2% |
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
FAQ
Is AIDX financially healthy?
20/20 Biolabs, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does AIDX pay a dividend?
No, 20/20 Biolabs, Inc. does not currently pay a dividend.
How profitable is AIDX?
In FY2025, 20/20 Biolabs, Inc. had a net margin of -182.8%.
What is the analyst price target for AIDX?
The average Wall-Street price target for 20/20 Biolabs, Inc. is $5.00, about 984.6% above the recent price, from 1 analysts.
Is AIDX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on 20/20 Biolabs, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.